X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-23 | AIMD | Ainos, Inc. | Ase Test, Inc. | 10% | P - Purchase | $0.00 | +29,476 | 58,887 | +100% | +$0 | ||||||
| D | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.45 | -100,000 | 1,462,223 | -6% | -$1,145,000 | |||||
2025-06-23 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $114.08 | -500 | 31,903 | -2% | -$57,042 | ||||||
| M | 2025-06-23 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.49 | -33,500 | 68,317 | -33% | -$351,384 | |||||
2025-06-20 | QURE | Uniqure N.V. | Springhorn Jeremy P. | Dir | S - Sale | $14.45 | -2,112 | 37,694 | -5% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Post Leonard E | Dir | S - Sale | $14.45 | -2,112 | 29,937 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale | $14.45 | -2,112 | 20,439 | -9% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Jacques Rachelle Suzanne | Dir | S - Sale | $14.45 | -2,112 | 28,346 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale | $14.45 | -3,336 | 56,879 | -6% | -$48,205 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale | $14.45 | -2,112 | 37,697 | -5% | -$30,518 | ||||||
2025-06-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $21.40 | -12,500 | 965,188 | -1% | -$267,458 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $14.45 | -2,112 | 34,190 | -6% | -$30,518 | ||||||
2025-06-20 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $7.99 | +5,603 | 3,091,127 | 0% | +$44,768 | ||||||
2025-06-20 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.13 | -17,808 | 443,839 | -4% | -$91,355 | ||||||
| M | 2025-06-20 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $5.13 | -4,135 | 109,920 | -4% | -$21,202 | |||||
2025-06-20 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.20 | +10,000 | 271,428 | +4% | +$12,000 | ||||||
2025-06-24 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $7.61 | -5,700 | 164,401 | -3% | -$43,377 | ||||||
| D | 2025-06-20 | MRUS | Merus N.V. | Silverman Peter B. | COO, GC | S - Sale+OE | $52.76 | -34,000 | 0 | -100% | -$1,793,840 | |||||
2025-06-24 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $4.05 | +5,000 | 360,900 | +1% | +$20,250 | ||||||
| M | 2025-06-20 | IMRX | Immuneering Corp | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | P - Purchase | $2.58 | +13,422 | 359,318 | +4% | +$34,616 | |||||
2025-06-20 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Chief Business Officer | P - Purchase | $2.53 | +1,900 | 5,800 | +49% | +$4,804 | ||||||
2025-06-20 | THAR | Tharimmune, Inc. | Gravitas Capital LP | Exec COB, 10% | P - Purchase | $1.48 | +337,838 | 732,424 | +86% | +$500,000 | ||||||
| M | 2025-06-20 | ORIC | Oric Pharmaceuticals, Inc. | You Angie | Dir | P - Purchase | $9.39 | +28,000 | 28,000 | New | +$262,899 | |||||
| M | 2025-06-18 | AIMD | Ainos, Inc. | Tsai Chun-Jung | Dir | S - Sale | $0.53 | -25,903 | 1,401,997 | -2% | -$13,624 | |||||
| DM | 2025-06-20 | AXSM | Axsome Therapeutics, Inc. | Murdock Hunter R. | GC | S - Sale+OE | $101.42 | -13,514 | 0 | -100% | -$1,370,647 | |||||
2025-06-20 | THAR | Tharimmune, Inc. | Parikh Sanam | Dir | P - Purchase | $1.45 | +1,000 | 1,770 | +130% | +$1,450 | ||||||
2025-06-20 | THAR | Tharimmune, Inc. | Appajosyula Sireesh | CEO | P - Purchase | $1.48 | +61,496 | 64,868 | >999% | +$90,973 | ||||||
| D | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | Foster Jonathan P. | CFO | P - Purchase | $0.37 | +270,270 | 287,587 | >999% | +$100,000 | |||||
| D | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | Klemp Walter V | CEO, Pres | P - Purchase | $0.37 | +675,675 | 743,607 | +995% | +$250,000 | |||||
2025-06-20 | ZLAB | Zai Lab Ltd | Lis William | Dir | S - Sale | $35.67 | -13,814 | 35,106 | -28% | -$492,745 | ||||||
2025-06-20 | SVRA | Savara Inc | Hawkins Richard J | Dir | P - Purchase | $2.04 | +48,225 | 115,466 | +72% | +$98,572 | ||||||
2025-06-20 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Dir | S - Sale | $37.39 | -2,405 | 15,344 | -14% | -$89,923 | ||||||
| M | 2025-06-18 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $11.46 | -1,142,273 | 50,641,965 | -2% | -$13,084,796 | |||||
2025-06-13 | RZLT | Rezolute, Inc. | Kim Young-Jin | Dir | P - Purchase | $3.25 | +1,230,769 | 8,573,336 | +17% | +$3,999,999 | ||||||
2025-06-13 | RZLT | Rezolute, Inc. | Kreher Nerissa | Dir | P - Purchase | $3.25 | +3,076 | 37,576 | +9% | +$9,997 | ||||||
2025-06-18 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $2.53 | +25,000 | 1,121,064 | +2% | +$63,188 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $54.84 | -6,620 | 549,867 | -1% | -$363,041 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Gangloff Scott A. | CTO | S - Sale | $54.84 | -848 | 23,452 | -3% | -$46,504 | ||||||
2025-06-20 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale | $54.59 | -875 | 31,698 | -3% | -$47,766 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $54.84 | -1,129 | 166,234 | -1% | -$61,914 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $54.84 | -1,634 | 57,521 | -3% | -$89,609 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $54.84 | -1,633 | 90,598 | -2% | -$89,554 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $54.84 | -1,453 | 256,594 | -1% | -$79,683 | ||||||
| D | 2025-06-20 | CNTA | Centessa Pharmaceuticals Plc | Saha Saurabh | CEO | S - Sale+OE | $12.63 | -55,000 | 259,017 | -18% | -$694,826 | |||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $1.20 | -486 | 26,530 | -2% | -$583 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $1.20 | -1,522 | 178,802 | -1% | -$1,825 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Harler Mary Beth | CEO | S - Sale | $1.20 | -1,522 | 338,181 | 0% | -$1,825 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $1.20 | -951 | 72,578 | -1% | -$1,140 | ||||||
| DM | 2025-06-17 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $6.74 | -339,720 | 912,419 | -27% | -$2,289,781 | |||||
2025-06-16 | QURE | Uniqure N.V. | Potts Jeannette | GC | S - Sale | $15.14 | -4,670 | 115,073 | -4% | -$70,704 | ||||||
| D | 2025-06-18 | SPRY | Ars Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Officer | S - Sale+OE | $16.00 | -15,000 | 7,696 | -66% | -$240,000 | |||||
| M | 2025-06-17 | TYRA | Tyra Biosciences, Inc. | Kaplan Gilla | Dir | S - Sale | $9.78 | -9,578 | 28,231 | -25% | -$93,700 | |||||
| AD | 2025-06-05 | IMUX | Immunic, Inc. | Tardio Jason | Pres, COO | P - Purchase | $0.79 | +12,512 | 12,512 | New | +$9,884 | |||||
| AD | 2025-06-04 | IMUX | Immunic, Inc. | Vitt Daniel | CEO, Dir | P - Purchase | $0.77 | +15,000 | 391,877 | +4% | +$11,550 | |||||
2025-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $13.37 | -10,139 | 109,414 | -8% | -$135,574 | ||||||
| D | 2025-06-20 | CLYM | Climb Bio, Inc. | Pimblett Emily | SVP, Finance, CAO | S - Sale+OE | $1.24 | -1,242 | 18,888 | -6% | -$1,540 | |||||
2025-06-18 | NKTX | Nkarta, Inc. | Hastings Paul J | CEO | S - Sale | $1.79 | -1,790 | 320,069 | -1% | -$3,204 | ||||||
2025-06-18 | ANAB | Anaptysbio, Inc | Fenton Dennis M | Dir | S - Sale | $23.97 | -3,015 | 4,965 | -38% | -$72,270 | ||||||
2025-06-18 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale | $23.97 | -3,015 | 4,965 | -38% | -$72,270 | ||||||
2025-06-17 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.20 | +15,000 | 261,428 | +6% | +$18,000 | ||||||
2025-06-16 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.65 | -335 | 461,647 | 0% | -$1,893 | ||||||
2025-06-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Dir | S - Sale | $5.65 | -284 | 42,242 | -1% | -$1,605 | ||||||
2025-06-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Dir | S - Sale | $5.65 | -594 | 102,326 | -1% | -$3,356 | ||||||
| M | 2025-06-17 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $8.06 | +33,442 | 2,976,203 | +1% | +$269,532 | |||||
2025-06-18 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $2.30 | +2,178 | 1,138,437 | 0% | +$4,999 | ||||||
2025-06-18 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $2.28 | +2,225 | 583,044 | 0% | +$5,071 | ||||||
| D | 2025-06-16 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $54.23 | -10,000 | 92,231 | -10% | -$542,306 | |||||
| D | 2025-06-16 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale+OE | $54.14 | -2,000 | 32,573 | -6% | -$108,272 | |||||
2025-06-18 | IMRX | Immuneering Corp | Zeskind Benjamin J. | Pres, CEO, 10% | P - Purchase | $2.39 | +21,000 | 3,197,779 | +1% | +$50,144 | ||||||
2025-06-16 | ARDX | Ardelyx, Inc. | Mott David M | Dir | P - Purchase | $3.63 | +200,000 | 2,896,871 | +7% | +$725,880 | ||||||
| DM | 2025-06-16 | AXSM | Axsome Therapeutics, Inc. | Murdock Hunter R. | GC | S - Sale+OE | $101.19 | -22,500 | 0 | -100% | -$2,276,850 | |||||
2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $1.15 | -6,422 | 401,241 | -2% | -$7,398 | ||||||
2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Pres, CEO | S - Sale | $1.11 | -30,474 | 1,541,488 | -2% | -$33,796 | ||||||
2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | CFO | S - Sale | $1.15 | -7,229 | 474,473 | -2% | -$8,328 | ||||||
2025-06-16 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale | $70.77 | -3,185 | 36,506 | -8% | -$225,402 | ||||||
2025-06-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $22.18 | -12,500 | 952,892 | -1% | -$277,292 | ||||||
2025-06-17 | ARVN | Arvinas, Inc. | Cacace Angela M | Chief Scientific Officer | S - Sale | $7.49 | -2,583 | 154,248 | -2% | -$19,347 | ||||||
2025-06-17 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Chief Program Officer | S - Sale | $30.24 | -911 | 50,392 | -2% | -$27,549 | ||||||
2025-06-16 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $52.26 | -2,000 | 67,530 | -3% | -$104,519 | ||||||
| D | 2025-06-16 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | GC | S - Sale+OE | $10.43 | -15,829 | 0 | -100% | -$165,096 | |||||
2025-06-16 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $266.50 | -422 | 278,434 | 0% | -$112,463 | ||||||
| M | 2025-06-16 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $262.11 | -1,647 | 1,768,858 | 0% | -$431,699 | |||||
| M | 2025-06-16 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $261.27 | -2,173 | 1,262,412 | 0% | -$567,742 | |||||
| M | 2025-06-16 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $263.33 | -5,140 | 54,270,337 | 0% | -$1,353,520 | |||||
| M | 2025-06-16 | XLO | Xilio Therapeutics, Inc. | Shannon James Samuel | Dir | P - Purchase | $0.69 | +70,000 | 70,000 | New | +$48,085 | |||||
2025-06-16 | XLO | Xilio Therapeutics, Inc. | Russo Rene | Pres, CEO | P - Purchase | $0.68 | +36,289 | 281,172 | +15% | +$24,680 | ||||||
| D | 2025-06-16 | NAMS | Newamsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $19.29 | -100,000 | 44,000 | -69% | -$1,929,141 | |||||
2025-06-16 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $19.50 | +8,584 | 6,823,153 | 0% | +$167,381 | ||||||
| D | 2025-06-16 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $28.28 | -17,300 | 61,563 | -22% | -$489,244 | |||||
| AM | 2024-05-13 | TRDA | Entrada Therapeutics, Inc. | Kim Peter S | Dir | P - Purchase | $14.63 | +50,000 | 117,412 | +74% | +$731,683 | |||||
| D | 2025-06-16 | VRNA | Verona Pharma Plc | Fisher Andrew | GC | S - Sale+OE | $11.53 | -80,000 | 359,999 | -18% | -$922,000 | |||||
| D | 2025-06-16 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $100.39 | -135,009 | 587,978 | -19% | -$13,553,744 | |||||
2025-06-16 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $98.82 | -10,686 | 130,637 | -8% | -$1,056,004 | ||||||
2025-06-16 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $11.00 | -8,500 | 443,642 | -2% | -$93,522 | ||||||
2025-06-16 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Gautam | Dir | S - Sale | $8.02 | -94,906 | 1,609,144 | -6% | -$761,146 | ||||||
2025-06-18 | NUVB | Nuvation Bio Inc. | Markel Stacy | Chief People Officer | P - Purchase | $1.71 | +10,000 | 29,591 | +51% | +$17,100 | ||||||
| M | 2025-06-16 | NUVB | Nuvation Bio Inc. | Sauvage Philippe | CFO | P - Purchase | $1.81 | +7,300 | 9,902 | +281% | +$13,216 | |||||
2025-06-16 | NUVB | Nuvation Bio Inc. | Sjogren Colleen | Chief Commercial Officer | P - Purchase | $1.81 | +50,000 | 81,000 | +161% | +$90,350 | ||||||
2025-06-16 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | Chief Regulatory Officer | P - Purchase | $1.79 | +50,000 | 50,000 | New | +$89,740 | ||||||
2025-06-16 | NUVB | Nuvation Bio Inc. | Hung David | Pres, CEO, 10% | P - Purchase | $1.79 | +500,000 | 59,281,054 | +1% | +$893,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |